Fujifilm AI service drug2drugs yields new bacterial inhibitor

Fujifilm's discovery came through joint research with Osaka University and others, and it centered on a protein tied to how pathogenic bacteria cause disease and resist drugs. The starting point was existing known compounds, and the AI drug-discovery support service "drug2drugs" was used to produce the new inhibitor. This places the work at the intersection of Fujifilm's AI service and antibacterial drug discovery, where finding new hits is difficult.

The body states that the outcome was highly active and was achieved through drug2drugs, which suggests the service can contribute to identifying candidate compounds from known chemical matter. That said, the article does not describe later stages such as optimization or testing. The significance for drugmakers and research partners is therefore likely to depend on whether this discovery can be translated into further development, an inference the body does not confirm.